Julie Saiki, the newly appointed Chief Strategy Officer of Adial Pharmaceuticals, Inc., has disclosed her ownership stakes in the company through a recent SEC filing. This filing is significant as it demonstrates Saiki's commitment to Adial's future and aligns her interests with those of shareholders. Her reported ownership includes a substantial number of stock options and shares, reflecting her vested interest in the company's performance.

Adial Pharmaceuticals, Inc. operates in the pharmaceutical preparations sector and is known for developing treatments for addiction and other serious health conditions. The company, which trades under the ticker symbol ADIL, has undergone significant changes recently, including a merger that may impact its strategic direction. The filing, dated October 30, 2026, marks a key moment for Saiki as she steps into her new role.

According to the SEC filing (accession number 0001213900-26-114578), Saiki currently holds 72,719 shares of common stock directly. Additionally, she has stock options to purchase 72,719 shares at an exercise price of $2.98, which vest over a period of time. Saiki also holds options for 31,915 shares at $1.57 and 67,021 shares at $0.63, with various vesting schedules. Furthermore, she has been granted 1,852,229 shares of Series A Preferred Stock, which can convert into common stock under specific conditions.

This disclosure is particularly relevant as it follows a recent merger involving Adial Pharmaceuticals and Azora Therapeutics, Inc. The merger was completed on June 11, 2026, and has positioned Adial for potential growth in the pharmaceutical industry. Saiki's ownership stakes could influence her decision-making as the company navigates the post-merger landscape and seeks to implement its strategic goals.

The filing indicates that Saiki's stock options and shares are intended to align her interests with those of the shareholders, a common practice in corporate governance. This alignment is crucial as Adial continues to develop its pipeline of treatments and expand its market presence. The pharmaceutical industry may see increased scrutiny on executive ownership disclosures, particularly as companies aim for greater transparency in their operations.

As Adial Pharmaceuticals moves forward, Saiki's role as Chief Strategy Officer will be pivotal in shaping the company's strategic initiatives. The filing does not specify what actions will follow this disclosure, but it underscores Saiki's commitment to the company's success.